BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 21075513)

  • 21. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells.
    Petrucci E; Pasquini L; Petronelli A; Saulle E; Mariani G; Riccioni R; Biffoni M; Ferretti G; Benedetti-Panici P; Cognetti F; Scambia G; Humphreys R; Peschle C; Testa U
    Gynecol Oncol; 2007 May; 105(2):481-92. PubMed ID: 17292950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined staining of TAG-72, MUC1, and CA125 improves labeling sensitivity in ovarian cancer: antigens for multi-targeted antibody-guided therapy.
    Chauhan SC; Vinayek N; Maher DM; Bell MC; Dunham KA; Koch MD; Lio Y; Jaggi M
    J Histochem Cytochem; 2007 Aug; 55(8):867-75. PubMed ID: 17478446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of MUC1-expressing ovarian cancer by C595 monoclonal antibody-conjugated SPIONs using MR imaging.
    Shahbazi-Gahrouei D; Abdolahi M
    ScientificWorldJournal; 2013; 2013():609151. PubMed ID: 24194685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
    Leonetti C; Biroccio A; D'Angelo C; Semple SC; Scarsella M; Zupi G
    Prostate; 2007 Sep; 67(13):1475-85. PubMed ID: 17654511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters.
    Song YJ; Qu CF; Rizvi SM; Li Y; Robertson G; Raja C; Morgenstern A; Apostolidis C; Perkins AC; Allen BJ
    Cancer Lett; 2006 Mar; 234(2):176-83. PubMed ID: 15961220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer.
    Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A
    Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specificity of seven monoclonal antibodies against p53 evaluated with Western blotting, immunohistochemistry, confocal laser scanning microscopy, and flow cytometry.
    Bonsing BA; Corver WE; Gorsira MC; van Vliet M; Oud PS; Cornelisse CJ; Fleuren GJ
    Cytometry; 1997 May; 28(1):11-24. PubMed ID: 9136751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
    Tang Y; Khan MA; Goloubeva O; Lee DI; Jelovac D; Brodie AM; Hussain A
    Clin Cancer Res; 2006 Jan; 12(1):169-74. PubMed ID: 16397039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells.
    Treeck O; Wackwitz B; Haus U; Ortmann O
    Gynecol Oncol; 2006 Aug; 102(2):292-9. PubMed ID: 16443261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines.
    Melichar B; Patenia R; Gallardo S; Melicharová K; Hu W; Freedman RS
    Gynecol Oncol; 2007 Mar; 104(3):707-13. PubMed ID: 17166566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
    Kersual N; Garambois V; Chardès T; Pouget JP; Salhi I; Bascoul-Mollevi C; Bibeau F; Busson M; Vié H; Clémenceau B; Behrens CK; Estupina P; Pèlegrin A; Navarro-Teulon I
    MAbs; 2014; 6(5):1314-26. PubMed ID: 25517316
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 15-Deoxy-Delta12,14-prostaglandin J2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors.
    Fulzele SV; Chatterjee A; Shaik MS; Jackson T; Ichite N; Singh M
    Anticancer Drugs; 2007 Jan; 18(1):65-78. PubMed ID: 17159504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.
    Heublein S; Page S; Mayr D; Schmoeckel E; Trillsch F; Marmé F; Mahner S; Jeschke U; Vattai A
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30642093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.
    Jutras S; Bachvarova M; Keita M; Bascands JL; Mes-Masson AM; Stewart JM; Gera L; Bachvarov D
    FEBS J; 2010 Dec; 277(24):5146-60. PubMed ID: 21078129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma.
    Hull A; Li Y; Bartholomeusz D; Hsieh W; Tieu W; Pukala TL; Staudacher AH; Bezak E
    Cells; 2022 Sep; 11(19):. PubMed ID: 36230945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1-positive cells in vitro but not in vivo.
    Shanehsazzadeh S; Gruettner C; Lahooti A; Mahmoudi M; Allen BJ; Ghavami M; Daha FJ; Oghabian MA
    Contrast Media Mol Imaging; 2015; 10(3):225-36. PubMed ID: 25327822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model.
    Bevis KS; McNally LR; Sellers JC; Della Manna D; Londoño Joshi A; Amm H; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2011 Apr; 121(1):193-9. PubMed ID: 21211830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Cell ELISA for the quantification of MUC1 mucin (CD227) expressed by cancer cells of epithelial and neuroectodermal origin.
    Falahat R; Wiranowska M; Gallant ND; Toomey R; Hill R; Alcantar N
    Cell Immunol; 2015; 298(1-2):96-103. PubMed ID: 26435344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer.
    Croce MV; Isla-Larrain MT; Rua CE; Rabassa ME; Gendler SJ; Segal-Eiras A
    J Histochem Cytochem; 2003 Jun; 51(6):781-8. PubMed ID: 12754289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma.
    Imai M; Ohta R; Okada N; Tomlinson S
    Int J Cancer; 2004 Jul; 110(6):875-81. PubMed ID: 15170670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.